Found: 36
Select item for more details and to access through your institution.
Cost-Effectiveness of Bevacizumab Biosimilar LY01008 Combined With Chemotherapy as First-Line Treatment for Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small Cell Lung Cancer.
- Published in:
- Frontiers in Pharmacology, 2022, v. 13, p. 1, doi. 10.3389/fphar.2022.832215
- By:
- Publication type:
- Article
Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
- Published in:
- Frontiers in Pharmacology, 2022, v. 12, p. 1, doi. 10.3389/fphar.2022.778505
- By:
- Publication type:
- Article
Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%.
- Published in:
- Frontiers in Pharmacology, 2022, v. 12, p. 1, doi. 10.3389/fphar.2021.803626
- By:
- Publication type:
- Article
First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.
- Published in:
- Frontiers in Pharmacology, 2021, v. 12, p. 1, doi. 10.3389/fphar.2021.788569
- By:
- Publication type:
- Article
Cost-Effectiveness of First-Line Versus Second-Line Pembrolizumab or Chemotherapy in Patients With Microsatellite-Instability-High/Mismatch Repair-Deficient Advanced Colorectal Cancer.
- Published in:
- Frontiers in Pharmacology, 2021, v. 12, p. 1, doi. 10.3389/fphar.2021.802942
- By:
- Publication type:
- Article
Cost-Effectiveness of Nivolumab Plus Cabozantinib Versus Sunitinib as a First-Line Treatment for Advanced Renal Cell Carcinoma in the United States.
- Published in:
- Frontiers in Pharmacology, 2021, v. 12, p. 1, doi. 10.3389/fphar.2021.736860
- By:
- Publication type:
- Article
Cost-Effectiveness of Frontline Treatment for Advanced Renal Cell Carcinoma in the Era of Immunotherapies.
- Published in:
- Frontiers in Pharmacology, 2021, v. 12, p. 1, doi. 10.3389/fphar.2021.718014
- By:
- Publication type:
- Article
Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer.
- Published in:
- Frontiers in Pharmacology, 2021, v. 12, p. 1, doi. 10.3389/fphar.2021.580459
- By:
- Publication type:
- Article
Evidence-based pharmacoeconomic evaluation of palbociclib in combination with letrozole versus docetaxel in combination with epirubicin in the first-line treatment of advanced breast cancer with epirubicin.
- Published in:
- Journal of Chinese Pharmaceutical Sciences, 2023, v. 32, n. 3, p. 214, doi. 10.5246/jcps.2023.03.019
- By:
- Publication type:
- Article
Study of the economic burden and influencing factors on stroke patients in Central China in the post-epidemic era.
- Published in:
- Journal of Chinese Pharmaceutical Sciences, 2022, v. 31, n. 7, p. 545, doi. 10.5246/jcps.2022.07.048
- By:
- Publication type:
- Article
A Review and Comparison of Methods for Recreating Individual Patient Data from Published Kaplan-Meier Survival Curves for Economic Evaluations: A Simulation Study.
- Published in:
- PLoS ONE, 2015, v. 10, n. 3, p. 1, doi. 10.1371/journal.pone.0121353
- By:
- Publication type:
- Article
Economic Outcomes of Maintenance Gefitinib for Locally Advanced/Metastatic Non-Small-Cell Lung Cancer with Unknown EGFR Mutations: A Semi-Markov Model Analysis.
- Published in:
- PLoS ONE, 2014, v. 9, n. 2, p. 1, doi. 10.1371/journal.pone.0088881
- By:
- Publication type:
- Article
Economic Evaluation of First-Line Adjuvant Chemotherapies for Resectable Gastric Cancer Patients in China.
- Published in:
- PLoS ONE, 2013, v. 8, n. 12, p. 1, doi. 10.1371/journal.pone.0083396
- By:
- Publication type:
- Article
A Trial-Based Cost-Effectiveness Analysis of Erlotinib Alone versus Platinum-Based Doublet Chemotherapy as First-Line Therapy for Eastern Asian Nonsquamous Non–Small-Cell Lung Cancer.
- Published in:
- PLoS ONE, 2013, v. 8, n. 3, p. 1, doi. 10.1371/journal.pone.0055917
- By:
- Publication type:
- Article
The Cost of Treating Advanced Non-Small Cell Lung Cancer: Estimates from the Chinese Experience.
- Published in:
- PLoS ONE, 2012, v. 7, n. 10, p. 1, doi. 10.1371/journal.pone.0048323
- By:
- Publication type:
- Article
Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer.
- Published in:
- PLoS ONE, 2021, v. 16, n. 11, p. 1, doi. 10.1371/journal.pone.0258605
- By:
- Publication type:
- Article
Sequences of biological treatments for patients with moderate-to-severe rheumatoid arthritis in the era of treat-to-target in China: a cost-effectiveness analysis.
- Published in:
- Clinical Rheumatology, 2022, v. 41, n. 1, p. 63, doi. 10.1007/s10067-021-05876-4
- By:
- Publication type:
- Article
PD-L1 Test-Based Strategy With Nivolumab as the Second-Line Treatment in Advanced NSCLC： A Cost-Effectiveness Analysis in China.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.745493
- By:
- Publication type:
- Article
Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.743765
- By:
- Publication type:
- Article
Cost-Effectiveness of Lorlatinib as a First-Line Therapy for Untreated Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.684073
- By:
- Publication type:
- Article
Cost-Effectiveness of ramucirumab plus paclitaxel as a second-line therapy for advanced gastric or gastro-oesophageal cancer in China.
- Published in:
- PLoS ONE, 2020, v. 15, n. 5, p. 1, doi. 10.1371/journal.pone.0232240
- By:
- Publication type:
- Article
Cost-Utility Analysis of the Newly Recommended Adjuvant Chemotherapy for Resectable Gastric Cancer Patients in the 2011 Chinese National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Gastric Cancer.
- Published in:
- PharmacoEconomics, 2014, v. 32, n. 3, p. 235, doi. 10.1007/s40273-013-0065-2
- By:
- Publication type:
- Article
Cost-Effectiveness Analysis of Adjuvant Therapy for Operable Breast Cancer from a Chinese Perspective: Doxorubicin plus Cyclophosphamide versus Docetaxel plus Cyclophosphamide.
- Published in:
- PharmacoEconomics, 2009, v. 27, n. 10, p. 873, doi. 10.2165/11314750-000000000-00000
- By:
- Publication type:
- Article
Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis.
- Published in:
- Clinical Drug Investigation, 2020, v. 40, n. 2, p. 129, doi. 10.1007/s40261-019-00869-3
- By:
- Publication type:
- Article
Clinical Benefit and Cost Effectiveness of Risk-Stratified Gastric Cancer Screening Strategies in China: A Modeling Study.
- Published in:
- PharmacoEconomics, 2022, v. 40, n. 7, p. 725, doi. 10.1007/s40273-022-01160-8
- By:
- Publication type:
- Article
First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: A United States-based cost-effectiveness analysis.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Cost-Effectiveness of Baricitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis After Methotrexate Failed in China.
- Published in:
- Rheumatology & Therapy, 2021, v. 8, n. 2, p. 863, doi. 10.1007/s40744-021-00308-w
- By:
- Publication type:
- Article
Cost-effectiveness of Triple Therapy vs. Biologic Treatment Sequence as First-line Therapy for Rheumatoid Arthritis Patients after Methotrexate Failure.
- Published in:
- Rheumatology & Therapy, 2021, v. 8, n. 2, p. 775, doi. 10.1007/s40744-021-00300-4
- By:
- Publication type:
- Article
Cost-Effectiveness of Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma in the United States.
- Published in:
- Advances in Therapy, 2021, v. 38, n. 12, p. 5710, doi. 10.1007/s12325-021-01950-0
- By:
- Publication type:
- Article
Cost-Effectiveness Analysis of Cemiplimab Versus Chemotherapy as First-Line Treatment in Advanced NSCLC with PD-L1 Expression Levels of at Least 50.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Cost-Effectiveness of Nivolumab Plus Ipilimumab Combined with Two Cycles of Chemotherapy as First-Line Treatment in Advanced Non-Small Cell Lung Cancer.
- Published in:
- Advances in Therapy, 2021, v. 38, n. 7, p. 3962, doi. 10.1007/s12325-021-01788-6
- By:
- Publication type:
- Article
First-Line Atezolizumab for Metastatic NSCLC with High PD-L1 Expression: A United States-Based Cost-Effectiveness Analysis.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Tofacitinib in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in China: A Cost-Effectiveness Analysis Based on a Mapping Algorithm Derived from a Chinese Population.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Cost-Effectiveness Analysis of Adding Daratumumab to a Regimen of Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Model-Based Cost-Effectiveness Analysis of Panitumumab Plus FOLFIRI for the Second-Line Treatment of Patients with Wild-Type Ras Metastatic Colorectal Cancer.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Model-Based Economic Evaluation of Ceritinib and Platinum-Based Chemotherapy as First-Line Treatments for Advanced Non-Small Cell Lung Cancer in China.
- Published in:
- 2019
- By:
- Publication type:
- journal article